tiprankstipranks
Trending News
More News >
Enanta Pharmaceuticals (ENTA)
NASDAQ:ENTA
US Market
Advertisement

Enanta Pharmaceuticals (ENTA) Income Statement

Compare
190 Followers

Enanta Pharmaceuticals Income Statement

Last quarter (Q3 2025), Enanta Pharmaceuticals's total revenue was $18.31M, an increase of 1.91% from the same quarter last year. In Q3, Enanta Pharmaceuticals's net income was $-18.25M. See Enanta Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 25Dec 24Dec 23Dec 22
Total Revenue
$ 65.32M$ ―$ 67.64M$ 79.20M$ 86.16M
Gross Profit
$ 65.32M$ ―$ 67.64M$ 79.20M$ 86.16M
Operating Expenses
$ 150.67M$ ―$ 189.33M$ 216.41M$ 210.00M
Depreciation and Amortization
$ 5.09M$ ―$ 2.34M$ 2.37M$ 2.97M
EBITDA
$ -70.78M$ ―$ -104.51M$ -123.48M$ -119.22M
Operating Income
$ -85.35M$ ―$ -121.69M$ -137.21M$ -123.84M
Other Income/Expenses
$ 1.80M$ ―$ 3.90M$ 6.21M$ 1.66M
Pretax Income
$ -83.55M$ ―$ -117.79M$ -131.00M$ -122.19M
Net Income
$ -81.89M$ ―$ -116.05M$ -133.82M$ -121.75M
Per Share Metrics
Basic EPS
$ -3.84$ ―$ -5.48$ -6.38$ -5.91
Diluted EPS
$ -3.84$ ―$ -5.48$ -6.38$ -5.91
Weighted Average Shares Outstanding
21.34M 21.16M 20.97M 20.60M
Weighted Average Shares Outstanding (Diluted)
21.34M 21.16M 20.97M 20.60M
Currency in USD

Enanta Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis